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AbstractÑ The idea that the purely phenomenological 
knowledge that we can extract by analysing large amounts of 
data can be useful in healthcare seems to contradict the desire of 
VPH researchers to build detailed mechanistic models for 
individual patients. But in practice no model is ever entirely 
phenomenological or entirely mechanistic. We propose in this 
position paper that big data analytics can be successfully 
combined with VPH technologies to produce robust and effective 
in silico medicine solutions. In order to do this, big data 
technologies must be further developed to cope with some specific 
requirements that emerge from this application. Such 
requirements are: working with sensitive data; analytics of 
complex and heterogeneous data spaces, including non-textual 
information; distributed data management under security and 
performance constraints; specialised analytics to integrate 
bioinformatics and systems biology information with clinical 
observations at tissue, organ and organisms scales; and 
specialised analytics to define the Òphysiological envelopeÓ 
during the daily life of each patient. These domain-specific 
requirements suggest a need for targeted funding, in which big 
data technologies for in silico medicine becomes the research 
priority.  
 
Index TermsÑ Virtual Physiological Human, big data, 
healthcare 
 
I. INTRODUCTION 
he birth of big data, as a concept if not as a term, is 
usually associated with a META Group report by Doug 
Laney entitled Ò3D Data Management: Controlling Data 
Volume, Velocity, and VarietyÓ published in 2001 [1]. Further 
developments now suggest big data problems are identified by 
the so-called Ò5VÓ: Volume (quantity of data), Variety (data 
from different categories), Velocity (fast generation of new 
data), Veracity (quality of the data), and Value (in the data) 
[2]. 
For a long time the development of big data technologies 
was inspired by business intelligence [3] and by big science 
(such as the Large Hadron Collider at CERN) [4].  But when 
in 2009 Google Flu, simply by analysing Google queries, 
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predicted flu-like illness rates as accurately as the CDCÕs 
enormously complex and expensive monitoring network [5], 
some analysts started to claim that all problems of modern 
healthcare could be solved by big data [6]. 
In 2005, the term Virtual Physiological Human (VPH) was 
introduced to indicate Òa framework of methods and 
technologies that, once established, will make possible the 
collaborative investigation of the human body as a single 
complex systemÓ [7, 8].  The idea was quite simple:  
- To reduce the complexity of living organisms, we 
decompose them into parts (cells, tissues, organs, organ 
systems) and investigate one part in isolation from the 
others. This approach has produced, for example, the 
medical specialties, where the nephrologist looks only at 
your kidneys, and the dermatologist only at your skin; this 
makes it very difficult to cope with multi-organ or 
systemic diseases, to treat multiple diseases (so common in 
the ageing population), and in general to unravel systemic 
emergence due to genotype-phenotype interactions. 
- But if we can recompose with computer models all the data 
and all the knowledge we have obtained about each part, 
we can use simulations to investigate how these parts 
interact with one another, across space and time and across 
organ systems. 
Though this may be conceptually simple, the VPH vision 
contains a tremendous challenge, namely the development of 
mathematical models capable of accurately predicting what 
will happen to a biological system. To tackle this huge 
challenge, multifaceted research is necessary: around medical 
imaging and sensing technologies (to produce quantitative 
data about the patientÕs anatomy and physiology) [9-11], data 
processing to extract from such data information that in some 
cases is not immediately available [12-14], biomedical 
modelling to capture the available knowledge into predictive 
simulations [15, 16], and computational science and 
engineering to run huge hypermodels (orchestrations of 
multiple models) under the operational conditions imposed by 
clinical usage [17-19]; see also the special issue entirely 
dedicated to multiscale modelling [20].  
But the real challenge is the production of that mechanistic 
knowledge, quantitative, and defined over space, time and 
across multiple space-time scales, capable of being predictive 
with sufficient accuracy. After ten years of research this has 
produced a complex impact scenario in which a number of 
target applications, where such knowledge was already 
available, are now being tested clinically; some examples of 
VPH applications that reached the clinical assessment stage 
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are: 
- The VPHOP consortium developed a multiscale modelling 
technology based on conventional diagnostic imaging 
methods that makes it possible, in a clinical setting, to 
predict for each patient the strength of their bones, how 
this strength is likely to change over time, and the 
probability that they will overload their bones during daily 
life. With these three predictions, the evaluation of the 
absolute risk of bone fracture in patients affected by 
osteoporosis will be much more accurate than any 
prediction based on external and indirect determinants, as 
it is in current clinical practice [21]. 
- More than 500,000 end-stage renal disease patients in 
Europe live on chronic intermittent haemodialysis 
treatment. A successful treatment critically depends on a 
well-functioning vascular access, a surgically created 
arterio-venous shunt used to connect the patient circulation 
to the artificial kidney. The ARCH project aimed to 
improve the outcome of vascular access creation and long-
term function with an image-based, patient-specific 
computational modelling approach. ARCH developed 
patient-specific computational models for vascular surgery 
that makes possible to plan such surgery in advance on the 
basis of the patientÕs data, and obtain a prediction of the 
vascular access function outcome, allowing an 
optimisation of the surgical procedure and a reduction of 
associated complications such as non-maturation.  A 
prospective study is currently running, coordinated by the 
Mario Negri Institute in Italy. Preliminary results on 63 
patients confirm the efficacy of this technology [22]. 
- Percutaneous coronary intervention (PCI) guided by 
Fractional Flow Reserve (FFR) is superior to standard 
assessment alone to treat coronaries stenosis. FFR-guided 
PCI results in improved clinical outcomes, a reduction in 
the number of stents implanted, and reduced cost. 
However, currently FFR is used in few patients, because it 
is invasive and it requires special instrumentation. A less 
invasive FFR would be a valuable tool.  The VirtuHeart 
project developed a patient-specific computer model that 
accurately predicts myocardial fractional flow reserve 
(FFR) from angiographic images alone, in patients with 
coronary artery disease. In a phase 1 study the methods 
showed an accuracy of 97%, when compared to standard 
FFR [23].  A similar approach, but based on Computed 
Tomography imaging, is even at a more advanced stage, 
having recently completed a phase 2 trial [24]. 
While these and some other VPH projects have reached the 
clinical assessment stage, quite a few other projects are still in 
the technological development, or pre-clinical assessment 
phase. But in some cases the mechanistic knowledge currently 
available simply turned out to be insufficient to develop 
clinically relevant models. 
So it is perhaps not surprising that recently, especially in the 
area of personalised healthcare (so promising but so 
challenging) some people have started to advocate the use of 
big data technologies as an alternative approach, in order to 
reduce the complexity that developing a reliable, quantitative 
mechanistic knowledge involves.  
This trend is fascinating from an epistemological point of 
view.  The VPH was born around the need to overcome the 
limitations of a biology founded on the collection of a huge 
amount of observational data, frequently affected by 
considerable noise, and boxed into a radical reductionism that 
prevented most researchers from looking at anything bigger 
than a single cell [25, 26].  Suggesting that we revert to a 
phenomenological approach where a predictive model is 
supposed to emerge not from mechanistic theories but by only 
doing high-dimensional big data analysis, may be perceived 
by some as a step toward that empiricism the VPH was created 
to overcome. 
In the following we will explain why the use of big data 
methods and technologies could actually empower and 
strengthen current VPH approaches, increasing considerably 
its chances of clinical impact in many ÒdifficultÓ targets. But 
in order for that to happen, it is important that big data 
researchers are aware that when used in the context of 
computational biomedicine, big data methods need to cope 
with a number of hurdles that are specific to the domain. Only 
by developing a research agenda for big data in computational 
biomedicine can we hope to achieve this ambitious goal. 
 
II. DOCTORS AND ENGINEERS: JOINED AT THE HIP 
As engineers who have worked for many years in research 
hospitals we recognise that clinical and engineering 
researchers share a similar mind-set. Both in traditional 
engineering and in medicine, the research domain is defined in 
terms of problem solving, not of knowledge discovery. The 
motto common to both disciplines is Òwhatever worksÓ.  
But there is a fundamental difference: engineers usually 
deal with problems related to phenomena on which there is a 
large body of reliable knowledge from physics and chemistry. 
When a good reliable mechanistic theory is not available 
engineers resort to empirical models, as far as they can solve 
the problem at hand.  But when they do this, they are left with 
a sense of fragility and mistrust, and they try to replace them 
as soon as possible with theory-based mechanistic models, 
which are both predictive and explanatory.  
Medical researchers deal with problems for which there is a 
much less well established body of knowledge; in addition, 
this knowledge is frequently qualitative or semi-quantitative, 
and obtained in highly controlled experiments quite removed 
from clinical reality, in order to tame the complexity involved.  
Thus, not surprisingly, many clinical researchers consider 
mechanistic models Òtoo simple to be trustedÓ, and in general 
the whole idea of a mechanistic model is looked upon with 
suspicion.  
But in the end Òwhatever worksÓ remains the basic 
principle. In some VPH clinical target areas where we can 
prove convincingly that our mechanistic models can provide 
more accurate predictions than the epidemiology-based 
phenomenological models, the penetration into clinical 
practice is happening. On the other hand, when our 
mechanistic knowledge is insufficient, the predictive accuracy 
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of our models is poor, and models based on 
empirical/statistical evidences are still preferred.  
The true problem behind this story is the competition 
between two methods of modelling nature that are both 
effective in certain cases. Big data can help computational 
biomedicine to transform this competition into collaboration, 
significantly increasing the acceptance of VPH technologies in 
clinical practice. 
 
III. BIG DATA VPH: AN EXAMPLE IN OSTEOPOROSIS 
In order to illustrate this concept we will use as a guiding 
example the problem of predicting the risk of bone fracture in 
a woman affected by osteoporosis, a pathological reduction of 
her bone mineralised mass [27]. The goal is to develop 
predictors that indicate whether the patient is likely to fracture 
over a given time (typically in the following ten years). If a 
fracture actually occurs in that period, this is the true value 
used to decide if the outcome prediction was right or wrong. 
Because the primary manifestation of the disease is quite 
simple (reduction of the mineral density of the bone tissue) not 
surprisingly researchers found that when such mineral density 
could be accurately measured in the regions where the most 
disabling fractures occurred (hip and spine), such 
measurement was a predictor of the risk of fracture [28]. In 
controlled clinical trials, where patients are recruited to 
exclude all confounding factors, the Bone Mineral Density 
(BMD) strongly correlated with the occurrence of hip 
fractures. Unfortunately, when BMD is used as a predictor, 
especially over randomised populations, the accuracy drops to 
60-65% [29]. Given that fracture is a binary event, tossing a 
coin would give us 50%, so this is considered not good 
enough. 
Epidemiologists run huge international, multicentre clinical 
trials where the fracture events are related to a number of 
observables; the data are then fitted with statistical models that 
provide phenomenological models capable of predicting the 
likelihood of fracture; the most famous, called FRAX, was 
developed by John Kanis at the University of Sheffield, UK, 
and is considered by the World Health Organisation the 
reference tool to predict risk of fractures. The predictive 
accuracy of FRAX is comparable to that of BMD, but it seems 
more robust for randomised female cohorts [30].  
In the VPHOP project, one of the flagship VPH projects 
funded by the Seventh Framework Program of the European 
Commission, we took a different approach: we developed a 
multiscale patient-specific model informed by medical 
imaging and wearable sensors, and used this model to predict 
the actual risk of fracture of the hip and at the spine, 
essentially simulating 10 years of the patientÕs daily life [18]. 
The results of the first clinical assessment, published only a 
few weeks ago, suggest that the VPHOP approach could 
increase the predictive accuracy to 80-85% [31]. Significant 
but not dramatic: no information is available yet on the 
accuracy with fully randomised cohorts, although we expect 
the mechanistic model to be less sensitive to biases. 
The goal of the VPHOP project was to replace FRAX; in 
doing this the research consortium took a considerable risk, 
common to most VPH projects, when a radically new and 
complex technology aims to replace an established standard of 
care. The difficulty arises from the need to step into the 
unknown, with the outcome remaining unpredictable until the 
work is complete. In our opinion big data technologies could 
change this high-risk scenario, allowing a progressive 
approach to modelling where predictions are initially 
generated only using the available data, and then progressively 
a priori knowledge is introduced about the physiology and the 
specific disease, captured into mechanistic predictive models. 
FRAX uses Poisson processes to define an epidemiological 
predictor for the risk of bone fracture in osteoporotic patients, 
which consider only the bone mineral density and a few 
personal and clinical information on the patient [32].  It has 
already been proposed that this could be extended to include 
also data related to the propensity to fall, such as stability 
tests, or wearable sensor recordings [33]. On the other hand, a 
vital piece of this puzzle is the ability of a patientÕs bone (as 
depicted in CT scan dataset) to withstand a given mechanical 
load without fracturing; this is something we can predict 
mechanistically with great accuracy [34].  The future are 
technologies that make possible (and easy) to combine 
statistical, population-based knowledge with mechanistic, 
patient-specific knowledge; in the case at hand, we could keep 
a stochastic representation of the fall, and of the resulting load, 
and model mechanistically the fracture event in itself. 
Can this example be considered a big data problem, in the 
light of the Ò5VÓ definition? 
- Volume: This is probably the big data criterion that 
current VPH research fits least well. Although the 
community wishes to exploit the vast entirety of clinical 
data records, often there is simply not the level of detail, 
or depth, that supports the association of parameters in 
the mechanistic models with the data in the clinical 
record. The datasets that support these analyses are often 
very expensive to acquire, and currently the penetration is 
limited. Nevertheless this is an important area of 
research, in which the VPH community could learn from, 
and exploit, existing technology from the big data 
community. 
- Variety: the variety is very high.  In the example at hand 
we would have clinical data, data from medical imaging, 
data from wearable sensors, lab exams, and simulation 
results.  This would include both structured and non 
structured data, with 3D imaging posing specific 
problems of data treatment such as automated voxel 
classification (see as examples [35-37]). 
- Velocity: osteoporosis is a chronic condition; as such all 
patients are expected to undergo a full specialist control 
every two years, where the totality of the examinations is 
repeated.  Regarding growth rate:  If to this we add that 
the ageing of the population is constantly increasing the 
number of patients affected, we face growth rates in the 
order of 55-60% every year. 
- Veracity: here there is a big divide between clinical 
research and clinical practice.  While data collected as 
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part of clinical studies are in general of good quality, 
clinical practice tends to generate low quality data.  This 
is due in part to the extreme pressure medical 
professionals face, but also to a lack of Òdata valueÓ 
culture; most medical professionals see the logging of 
data a bureaucratic need and a waste of time that distracts 
them from the care of their patients.  
- Value: the potential value associated with these data is 
very high. The cost of osteoporosis, including 
pharmacological intervention in the EU in 2010 was 
estimated at !37 billion [38]. Moreover, in general, 
healthcare expenditure in most developed countries is 
astronomical: the 2013/2014 budget for NHS England 
was £95.6 billion, with an increase over the previous year 
of 2.6%, at a time when all public services in the UK are 
facing hard cuts.  In OECD countries we spend on 
average USD$3,395 per year per inhabitant in healthcare 
(source: OECD 2011).  But the real value of Big Data 
Analytics in healthcare still remains to be proven.  We 
believe this is largely due to the need for much more 
sophisticated analytics, which incorporate a priori 
knowledge of pathophysiology; this is exactly what the 
VPH has to offer to big data analytics in healthcare. 
 
IV. FROM DATA TO THEORY: A CONTINUUM 
Modern big data technologies make it possible in a short 
time to analyse a large collection of data from thousands of 
patients, identify clusters and correlations, and develop 
predictive models using statistical or machine-learning 
modelling techniques [39, 40]. In this new context it would be 
feasible to take all the data collected in all past epidemiology 
studies - for example, those used to develop FRAX - and 
continue to enrich them with new studies where not only new 
patients are added, but different types of information are 
collected.  
Another mechanism that in principle very high-throughput 
technologies make viable for exploration is the normalisation 
of digital medical images to conventional space-time reference 
systems, using elastic registration methods [41-43], followed 
by the treatment of the quantities expressed by each voxel 
value in the image as independent data quanta. The voxel 
values of the scan then become another medical dataset, 
potentially to be correlated with average blood pressure, body 
weight, age, or any other clinical information. 
Using statistical modelling or machine learning techniques 
we may obtain good predictors valid for the range of the data 
sets analysed; if a database contains outcome observables for a 
sub-set of patients, we will be able to compute automatically 
the accuracy of such a predictor. Typically the result of this 
process would be a potential clinical tool with known 
accuracy; in some cases the result would provide a predictive 
accuracy sufficient for clinical purposes, in others a higher 
accuracy might be desirable. 
In some cases there is need for an explanatory theory, which 
answers the ÒhowÓ question, and which may be used in a 
wider context than that a statistical model normally is. As a 
second step, one could use the correlation identified by the 
empirical modelling to elaborate possible mechanistic 
theories.  Given that the available mechanistic knowledge is 
quite incomplete, in many cases we will be able to express a 
mathematical model only for a part of the process to be 
modelled; various Ògrey-boxÓ modelling methods have been 
developed in the last few years that allow one to combine 
partial mechanistic knowledge with phenomenological 
modelling [44]. 
The last step is where physiology, biochemistry, 
biomechanics, and biophysics mechanistic models are used. 
These models contain a large amount of validated knowledge, 
and require only a relatively small amount of patient-specific 
data to be properly identified.  
In many cases these mechanistic models are extremely 
expensive in terms of computational cost; therefore input-
output sets of these models may also be stored in a data 
repository in order to identify reduced-order models (also 
referred as ÔsurrogateÕ models and Ômeta-modelsÕ) that 
accurately replace a computationally expensive model with a 
cheaper/faster simulation [45]. Experimental design methods 
are used to choose the input and output parameters or 
variables with which to run the mechanistic model in order to 
generate the meta-modelÕs state space description of the input-
output relations Ð which is often replaced with a piecewise 
partial least-squares regression (PLSR) approximation [46].  
Another approach is to use Nonlinear AutoRegressive Moving 
Average model with eXogenous inputs (NARMAX) in the 
framework of non-linear systems identification [47]. 
It is interesting to note that no real model is ever fully 
Òwhite-boxÓ. In all cases, some phenomenological modelling 
is required to define the interaction of the portion of reality 
under investigation with the rest of the universe. If we accept 
that a model describes a process at a certain characteristic 
space-time scale, everything that happens at any scale larger 
or smaller than that must also be accounted for 
phenomenologically.  Thus, it is possible to imagine a 
complex process being modelled as an orchestration of sub-
models, each predicting a part of the process (for example at 
different scales), and we can expect that, while initially all 
sub-models will be phenomenological, more and more will 
progressively include some mechanistic knowledge.  
The idea of a progressive increase of the explanatory 
content of a hypermodel is not fundamentally new; other 
domains of science already pursued the approach described 
here. But in the context of computational biomedicine this is 
an approach used only incidentally, and not as a systematic 
strategy for the progressive refinement of clinical predictors.  
 
V. BIG DATA FOR COMPUTATIONAL BIOMEDICINE: 
REQUIREMENTS 
In a complex scenario such as the one described above, are 
the currently available technologies sufficient to cope with this 
application context? 
The brief answer is no. A number of shortcomings that need 
to be addressed before big data technologies can be effectively 
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and extensively used in computational biomedicine.  Here we 
list five of the most important. 
 
A. Confidential data 
The majority of big data applications deal with data that do 
not refer to an individual person. This does not exclude the 
possibility that their aggregated information content might not 
be socially sensitive, but very rarely is it possible to reconnect 
such content to the identity of an individual. 
In the cases where sensitive data are involved, it is usually 
possible to collect and analyse the data at a single location; so 
this becomes a problem of computer security; within the 
secure box, the treatment of the data is identical to that of non-
sensitive data.  
Healthcare poses some peculiar problems in this area. First, 
all medical data are highly sensitive, and in many developed 
countries are considered legally owned by the patient, and the 
healthcare provider is required to respect patient 
confidentiality. The European parliament is currently involved 
in a complex debate about data protection legislation, where 
the need for individual confidentiality can be in conflict with 
the needs of society [48].  
Secondly, in order to be useful for diagnosis, prognosis or 
treatment planning purposes the data analytics results must in 
most cases be re-linked to the identity of the patient. This 
implies that the clinical data cannot be fully and irreversibly 
anonymised before leaving the hospital, but requires complex 
pseudo-anonymisation procedures. Normally the clinical data 
are pseudo-anonymised so as to ensure a certain k-anonymity 
[49], which is considered legally and ethically acceptable. But 
when the data are, as part of big data mash-ups, relinked to 
other data, for example from social networks or other public 
sources, there is a risk that the k-anonymity of the mash-up 
can be drastically reduced. Specific algorithms need to be 
developed that prevent such data aggregation when the k-
anonymity could drop below the required level.  
 
B. Big data: big size or big complexity? 
Consider two data collections: 
- In one case we have 500 TB of log data from a popular 
web site: a huge list of text strings, typically encoding 7-10 
pieces of information for transaction, for example the log file 
of a very popular web site. 
- In the other, we have a full VPHOP dataset for 100 
patients, a total of 1TB; for each patient we have 122 textual 
information items that encode the clinical data, three medical 
imaging datasets of different types, 100 signal files from 
wearable sensors, a neuromuscular dynamics output database, 
an organ-level model with the results, and a tissue-scale model 
with the predictions of bone remodelling over 10 years. This is 
a typical VPH data folder; some applications require even 
more complex data spaces.  
Which one of these two data collections should be 
considered big data? We suggest that the idea held by some 
funding agencies, that the only worthwhile applications are 
those targeting data collections over a certain size, trivialises 
the problem of big data analytics. While the legacy role of big 
data analysis is the examination of large amounts of scarcely 
complex data, the future lies in the analysis of complex data, 
eventually even in smaller amounts.  
 
C. Integrating bioinformatics, systems biology, and 
phenomics data 
Genomics and post-genomics technologies produce very 
large amounts of raw data about the complex biochemical 
processes that regulate each living organism; nowadays a 
single deep-sequencing dataset can exceed 1TB [50]. More 
recently we have started to see the generation of Òdeep 
phenotypingÓ data, where biochemical, imaging, and sensing 
technologies are used to quantify complex phenotypical traits 
and link them to the genetic information [51]. These data are 
processed with specialised big data analytics techniques, 
which come from bioinformatics, but recently there is growing 
interest in building mechanistic models of how the many 
species present inside a cell interact along complex 
biochemical pathways. Because of the complexity and the 
redundancy involved, linking this very large body of 
mechanistic knowledge to the higher-order cell-cell and cell-
tissue interactions remains very difficult, primarily for the data 
analytics problems it involves.  But when this is possible, 
genomics research results finally link to clinically relevant 
pathological signs, observed at tissue, organ, and organism 
scales, opening the door to a true systems medicine. 
 
D. Where are the data? 
In big data research, the data are usually stored and 
organised in order to maximise the efficiency of the data 
analytics process.  In the scenario described here, however, it 
is possible that parts of the simulation workflow require 
special hardware, or can be run only on certain computers 
because of licence limitations. Thus one ends up trading the 
needs of the data analytics part with those of the VPH 
simulation part, always ending up with a sub-optimal solution.  
In such complex simulation scenarios, data management 
becomes part of the simulation process; clever methods must 
be developed to replicate/store certain portions of the data 
within organisations and at locations that maximise the 
performance of the overall simulation. 
 
E. The physiological envelope and the predictive avatar  
In the last decade there has been a great deal of interest in 
the generation and analysis of patient-specific models. 
Enormous progress has been made in the integration of image 
processing and engineering analysis, with many applications 
in healthcare across the spectrum from orthopaedics to 
cardiovascular systems and often multiscale models of disease 
processes, including cancer, are included in these analyses. 
Very efficient methods, and associated workflows, have been 
developed that support the generation of patient-specific 
anatomical models based on exquisite three and four-
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dimensional medical images [52, 53]. The major challenge 
now is to use these models to predict acute and longer-term 
physiological and biological changes that will occur under the 
progression of disease and under candidate interventions, 
whether pharmacological or surgical. There is a wealth of data 
in the clinical record that could support this, but its 
transformation into relevant information is enormously 
difficult.  
All engineering models of human organ systems, whether 
focused on structural or fluid flow applications, require not 
only the geometry (the anatomy) but also constitutive 
equations and boundary conditions. The biomedical 
engineering community is only beginning to learn how to 
perform truly personalised analysis, in which these parameters 
are all based on individual physiology. There are many 
challenges around the interpretation of the data that is 
collected in the course of routine clinical investigation, or 
indeed assembled in the Electronic Health Record or Personal 
Health Records. Is it possible to predict the threat or challenge 
conditions (e.g. limits of blood pressure, flow waveforms, 
joint loads), and their frequency or duration, from the data that 
is collected? How can the physiological envelope of the 
individual be described and characterised? How many 
analyses need to be done to characterise the effect of the 
physiological envelope on the progression of disease or on the 
effectiveness of treatment? How are these analyses best 
formulated and executed computationally? How is information 
on disease interpreted in terms of physiology? As an example, 
how (quantitatively) should we adapt a patient-specific 
multiscale model of coronary artery disease to reflect the 
likelihood that a diabetic patient has impaired coronary 
microcirculation? At a more generic level, how can the priors 
(in terms of physical relationships) that are available from 
engineering analysis be integrated into machine learning 
operations in the context of digital healthcare, or alternatively 
how can machine learning be used to characterise the 
physiological envelope to support meaningful diagnostic and 
prognostic patient-specific analyses? For a simple example, 
consider material properties: arteries stiffen as an individual 
ages, but diseases such as moyamoya syndrome can also 
dramatically affect arterial stiffness; how should models be 
modified to take into account such incidental data entries in 
the patient record? 
 
VI. CONCLUSIONS 
Although sometimes overhyped, big data technologies do 
have great potential in the domain of computational 
biomedicine, but their development should take place in 
combination with other modelling strategies, and not in 
competition. This will minimise the risk of research 
investments, and will ensure a constant improvement of in 
silico medicine, favouring its clinical adoption. 
We have described five major problems that we believe 
need to be tackled in order to have an effective integration of 
big data analytics and VPH modelling in healthcare.  For some 
of these problems there is already an intense on-going research 
activity, which is comforting.  
For many years the high-performance computing world was 
afflicted by a one-size-fits-all mentality that prevented many 
research domains from fully exploiting the potential of these 
technologies; more recently the promotion of centres of 
excellence, etc., targeting specific application domains, 
demonstrates that the original strategy was a mistake, and that 
technological research must be conducted at least in part in the 
context of each application domain.   
It is very important that the big data research community 
does not repeat the same mistake. While there is clearly an 
important research space examining the fundamental methods 
and technologies for big data analytics, it is vital to 
acknowledge that it is also necessary to fund domain-targeted 
research that allows specialised solutions to be developed for 
specific applications. Healthcare in general, and computational 
biomedicine in particular, seems a natural candidate for this. 
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